Fluconazole versus itraconazole for candida esophagitis in acquired immunodeficiency syndrome. Candida Esophagitis
Open accessAbstract
Backgrounds & aims Contrasting opinions exist about the pharmacological treatment of esophageal candidiasis in patients with acquired immunodeficiency syndrome (AIDS). The aim of this study was to assess the long-term efficacy of fluconazole and itraconazole treatment.Methods This study evaluated 2213 human immunodeficiency virus-positive patients at first episode of esophageal candidiasis diagnosed by endoscopy; 1105 received fluconazole and 1108 received itraconazole. The endoscopic and clinical response to treatment was assessed periodically until the end of the follow-up period (1 year).Results At week 2, endoscopic cure occurred in 81.2% of patients treated with fluconazole and in 65.6% of patients treated with itraconazole (P < 0.001). Clinical cure was observed in 81.5% of patients treated with fluconazole and in 75.2% of patients treated with itraconazole (P < 0.001). At the end of the follow-up period, endoscopic and clinical cure were observed in 96% of patients treated with fluconazole and in 95.6% of patients treated with itraconazole (P = 0.788), with similar differences by intention-to-treat analysis (93.6% vs. 93.3%; P = 0.853). Treatment failure was observed in 22.3% of fluconazole-treated patients and in 26.6% of itraconazole-treated patients (P = 0.022).Conclusions Fluconazole and itraconazole are provided with good long-term therapeutic efficacy in the treatment of Candida esophagitis in patients with AIDS. Fluconazole is associated with a higher rate of cure than itraconazole in short-term treatment.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Fluconazole is superior to ketoconazole, itraconazole capsules, and flucytosine for treatment of esophageal candidiasis.
“Fluconazole is superior to ketoconazole, itraconazole capsules, and flucytosine for the treatment of esophageal candidiasis [278][279][280].”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [279]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The publisher hasn’t deposited this paper’s reference list.
Research works printed but not linked: 13
- References therapy. N Engl J Med 1994; 330:263 -272.
- Deschamps MM, Pape JW, Verdier RI, DeHovitz J, Thomas F, Ann Intern Med 1988; 109:502 -504.
- Johnson WD Jr. Treatment of Candida esophagitis in AIDS pa- 18. Lake-Bakaar G, Tom W, Lake-Bakaar D, Gupta N, Beidas S, Elsakr tients. Am J Gastroenterol 1988; 83:20 -21.
- M, Straus EW. Gastropathy and ketoconazole malabsorption in 3. Connolly GM, Hawkins D, Harcourt-Webster JN, Parson PA, Hu- the acquired immunodeficienc syndrome (AIDS). Ann Intern Med sain OA, Gazzard BG. Oesophageal symptoms, their causes, 1988; 109:471 -473. treatment and prognosis in patients with the acquired immunode- 19.
- Smith D, Woestenborghs R, Heykants J, Gazzard B. The pharma- ficienc syndrome. Gut 1989; 30:1033 -1039. cokinetics of oral itraconazole in AIDS patients (abstr WB 2174).
- Smith DE, Midgley J, Allan M, Connolly GM, Gazzard BG. Itracona- Florence: Proceedings of the 7th International Conference on zole vs ketakonazole in the treatment of oral and oesophageal AIDS, June 16 -21, 1991:225. candidosis in patients infected with HIV. AIDS 1991; 5:1367 - 1371. Received October 16, 1995. Accepted July 30, 1996.
- Laine L, Dretler RH, Conteas CN, Tuazon C, Koster FM, Sattler Address requests for reprints to: Giuseppe Barbaro, M.D., Viale F, Squires K, Islam MZ. Fluconazole compared with ketoconazole Anicio Gallo no. 63, 00174 Rome, Italy. Fax: (39) 6-7102889. for the treatment of Candida esophagitis in AIDS. A randomized Members of the Candida Esophagitis Multicenter Italian Study Ex- trial. Ann Intern Med 1992; 117:655 -660.
- Barbaro, M.D., Gabriella Di Lorenzo, M.D., Maurizio Soldini, M.D., 7. Barbaro G, Di Lorenzo G. Comparison of therapeutic activity of and Sandro Parrotto, M.D.); Department of Infectious Diseases and fluconazol and itraconazole in the treatment of esophageal can- Gastroenterology, Istituto Ricovero e Cura a Carattere Scientifico didiasis in AIDS patients: a double-blind, randomized, controlled Policlinico S. Matteo, University of Pavia, Pavia (Giorgio Barbarini, clinical study. Ital J Gastroenterol 1995; 27:175 -180.
- M.D., and Willi Calderon, M.D.); and Department of Clinical Pharma- 8. Kodsi BE, Wicremesinghe PC, Kozinn PJ, Iswara K, Goldberg PK. cology, University of Pavia, Pavia, Italy (Pierangela Alcini, M.D.). Can- Candida esophagitis. A prospective study of 27 cases. Gastroen- dida Esophagitis Multicenter Italian Study Centers include the De- terology 1976; 71:715 -719. partment of Infectious Diseases and Gastroenterology, University La 9. Armitage P, Berry G. Statistical methods in medical research. Sapienza, Rome (Franco De Rosa, M.D., and Vittorio M. Rinaldi, 2nd ed. Oxford, England: Blackwell Scientific 1987.
- Grant SM, Clissold SP. Itraconazole: a review of its pharmacody- pendenti Vigevano (Sergio Edo, M.D.); AIDS Center, State Prison namic and pharmacokinetic properties, and therapeutic potential of Vigevano, Vigevano (Fausto Barbieri, M.D.); Servizio Assistenza in superficia and systemic myocoses. Drugs 1990; 39:877 - Tossicodependenti Abbiategrasso (Silvano Lopez, M.D.); Servizio As- 916.
- Just-Nubling G, Gentschew G, Dohle M, Bottinger C, Helm EB, Division of Infectious Diseases, General Hospital, Foggia (Benvenuto Stille W. Fluconazole in the treatment of oropharingeal can- Grisorio, M.D.); Servizio Assistenza Tossicodependenti Foggia (Bruno didosis in HIV-positive patients. Mycoses 1990; 33:435 -440.
- Bonacini M, Young T, Laine L. The causes of esophageal symp- vanni Salandra, M.D.); AIDS Center, State Prison of Lucera, Lucera toms in human immunodeficienc virus infection. A prospective (Alfonso Catanzaro, M.D.); AIDS Center, State Prison of San Severo, study of 110 patients. Arch Intern Med 1991; 151:1567 -1572.
- Saag MS, Dismukes WE. Azole antifungal agents: emphasis on gery II, University La Sapienza, Rome, Italy (Fabio Gaj, M.D., and new triazoles. Antimicrob Agents Chemother 1988; 32:1 -8.
Cited by
Sorted by citations
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200 · see citing works
“sules, and flucytosine, and is comparable to itraconazole solution for the treatment of esophageal candidiasis [558, 559]; up to 80% of patients with fluconazole-refractory infections will re-”
BackgroundPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · see citing works
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · see citing works
Practice Guidelines for the Treatment of Candidiasis
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313749 · Cited by 927 · see citing works
“Fluconazole is superior to ketoconazole, itraconazole capsules, and flucytosine for the treatment of esophageal candidiasis [146–148].”
BackgroundUllmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12041 · Cited by 334 · see citing works
Krause, D. S., Simjee, A. E., van Rensburg, C. E. J., Viljoen, J., Walsh, T. J., Goldstein, B. P., Wible, M., & Henkel, T. (2004) · Clinical Infectious Diseases · doi:10.1086/423378 · Cited by 241 · see citing works
Reviews Of Anti‐infective Agents: Anidulafungin: A Novel Echinocandin
Vázquez, J. A., & Sobel, J. D. (2006) · Clinical Infectious Diseases · doi:10.1086/505204 · Cited by 197 · see citing works
Ruhnke, M., Rickerts, V., Cornely, O. A., Buchheidt, D., Glöckner, A., Heinz, W., Höhl, R., Horré, R., Karthaus, M., Kujath, P., et al. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02040.x · Cited by 137 · see citing works
Lortholary, O., Πετρίκκος, Γ., Akova, M., Arendrup, M. C., Arıkan-Akdağlı, S., Bassetti, M., Billé, J., Calandra, T., Castagnola, E., Cornely, O. A., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12042 · Cited by 108 · see citing works
“Itraconazole solution B I [49][46][47] Echinocandins can be used in patients who cannot swallow but not better than Fluconazole C I [55][56][57][53][54] Higher relapse rate with caspofungin and anidulafungin vs fluconazole Ketoconazole D I [48][42] Any i.”
BackgroundCornely, O. A. (2008) · Infection · doi:10.1007/s15010-008-7357-z · Cited by 97 · see citing works
Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection
Vazquez, J. (2010) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s6660 · Cited by 81 · see citing works
Current Options in Antifungal Pharmacotherapy
Mohr, J., Johnson, M. D., Cooper, T., Lewis, J. S., & Ostrosky‐Zeichner, L. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.5.614 · Cited by 85 · see citing works
“Fluconazole 100 mg/day was compared with ketoconazole 200 mg/day for treatment of esophageal candidiasis in 169 patients with AIDS.141 Therapy was continued for 2 weeks after symptom resolution, for a maximum of 8 weeks.”
ResultInfluentialAnidulafungin: A new echinocandin with a novel profile
Vazquez, J. A. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.06.010 · Cited by 78 · see citing works
Vázquez, J. A. (2000) · HIV Clinical Trials · doi:10.1310/t7a7-1e63-2ka0-jkwd · Cited by 74 · see citing works
Infections of the esophagus: an update on risk factors, diagnosis, and management
Hoversten, P., Kamboj, A. K., & Katzka, D. A. (2018) · Diseases of the Esophagus · doi:10.1093/dote/doy094 · Cited by 71 · see citing works
Overview of treatment options for invasive fungal infections
Pound, M. W., Townsend, M. L., DiMondi, V. P., Wilson, D. T., & Drew, R. H. (2011) · Medical Mycology · doi:10.3109/13693786.2011.560197 · Cited by 69 · see citing works
Options for the Management of Mucosal Candidiasis in Patients with AIDS and HIV Infection
Vázquez, J. A. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.1.76.30509 · Cited by 62 · see citing works
Petraitis, V., Petraitienė, R., Groll, A. H., Sein, T., Schaufele, R. L., Lyman, C. A., Francesconi, A., Bacher, J., Piscitelli, S. C., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.471-479.2001 · Cited by 53 · see citing works
“Esophageal candidiasis is one of the most common opportunistic fungal infections in immunocompromised patients, including human immunodeficiency virus (HIV)-positive patients and those who are immunosuppressed as a result of underlying diseases or medications (2, 35).”
BackgroundViljoen, J., Azie, N. E., Schmitt-Hoffmann, A.-H., & Ghannoum, M. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04586-14 · Cited by 48 · see citing works
“The duration of treatment was based on disease severity and clinical response and was consistent with previous clinical trials, current clinical practice, and guidelines for the treatment of esophageal candidiasis (3, 7, 25).”
MethodInvasive Oesophageal Candidiasis
Vázquez, J. A. (2003) · Drugs · doi:10.2165/00003495-200363100-00004 · Cited by 47 · see citing works
Conte, J. E., Golden, J. A., Kipps, J., McIver, M., & Zurlinden, E. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.3823-3827.2004 · Cited by 41 · see citing works
Lashof, A. M. L. O., Bock, R. D., Herbrecht, R., Pauw, B. E. D., Krcmery, V., Aoun, M., Akova, M., Cohen, J., Šiffnerová, H., Egyed, M., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.03.003 · Cited by 40 · see citing works
Update on antifungal treatment of invasive Candida and Aspergillus infections
Maschmeyer, G., & Ruhnke, M. (2004) · Mycoses · doi:10.1111/j.1439-0507.2004.01003.x · Cited by 40 · see citing works
Mucosal and Systemic Fungal Infections in Patients with AIDS
Ruhnke, M. (2004) · Drugs · doi:10.2165/00003495-200464110-00002 · Cited by 38 · see citing works
Decline in Esophageal Candidiasis and Use of Antimycotics in European Patients with HIV
Mocroft, A., Oancea, S. C., van Lunzen, J., et al. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41949.x · Cited by 36 · see citing works
Petraitis, V., Petraitienė, R., Kelaher, A. M., Sarafandi, A. A., Sein, T., Mickiene, D., Bacher, J. D., Groll, A. H., & Walsh, T. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.3959-3967.2004 · Cited by 36 · see citing works
Oesophageal Candidiasis in Elderly Patients
Weerasuriya, N., & Snape, J. (2008) · Drugs & Aging · doi:10.2165/00002512-200825020-00004 · Cited by 34 · see citing works
Bhagani, S. R. (2011) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s9274 · Cited by 25 · see citing works
Treatment of gastrointestinal infections
Banerjee, S., & LaMont, J. T. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70006-0 · Cited by 23 · see citing works
Spec, A., Thompson, G. R., Miceli, M. H., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae010 · Cited by 21 · see citing works
“Treatment discontinuation was required in 1%– 2%, similar to our study [36–38].”
ResultZaidi, S. A., & Cervia, J. S. (2002) · Journal of the International Association of Physicians in AIDS Care · doi:10.1177/154510970200100204 · Cited by 20 · see citing works
Antifungal therapy - state of the art at the beginning of the 21st century
Polak, A. (2003) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7974-3_4 · Cited by 19 · see citing works
[Oesophageal candidiasis: clinical and mycological analysis].
Olmos, M. A., Araya, V., Concetti, H., et al. (2005) · PubMed · Cited by 17 · see citing works
The therapy of gastrointestinal infections associated with the acquired immunodeficiency syndrome
Wilcox, C. M., & Mönkemüller, K. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.00159.x · Cited by 17 · see citing works
Pappas, P. G., Kauffman, C. A., Andes, D. R., Benjamin, D. K., Calandra, T., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B. J., Ostrosky-Zeichner, L. L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/598961 · Cited by 15 · see citing works
Gastrointestinal Disorders in HIV
Serlin, M. H., & Dieterich, D. T. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-2882-6.50027-7 · Cited by 16 · see citing works
Anidulafungin: a novel echinocandin
Vazquez, J. A. (2006) · Therapy · doi:10.2217/14750708.3.1.39 · Cited by 13 · see citing works
Bonacini, M. (2001) · Digestive and Liver Disease · doi:10.1016/s1590-8658(01)80722-2 · Cited by 12 · see citing works
Antifungal therapy, an everlasting battle
Polak, A. (1997) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8863-9_7 · Cited by 12 · see citing works
Dockrell, D. H., O’Shea, D., Cartledge, J. D., & Freedman, A. (2019) · HIV Medicine · doi:10.1111/hiv.12806 · Cited by 11 · see citing works
Esophageal Disease in Patients with AIDS: Diagnosis and Treatment
Bonacini, M., & Laine, L. (1998) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/s1052-5157(18)30233-2 · Cited by 11 · see citing works
4 Gastrointestinal opportunistic infections
Beeching, N. J., Jones, R., & Gazzard, B. (2011) · HIV Medicine · doi:10.1111/j.1468-1293.2011.00944_5.x · Cited by 8 · see citing works
Matsuo, T., Singh, B. S., Wurster, S., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106172 · Cited by 8 · see citing works
Liver cirrhosis as a predisposing factor for esophageal candidiasis
Ou, T., Huang, H., Hsieh, T., Chang, W., Chu, H.-C., Hsu, C., Shih, Y., Huang, T., Chen, P., & Lin, H. (2014) · Advances in digestive medicine · doi:10.1016/j.aidm.2013.09.005 · Cited by 8 · see citing works
Inflammatory Disorders of the Esophagus
Bennett, A. E., Goldblum, J. R., & Odze, R. D. (2009) · Elsevier eBooks · doi:10.1016/b978-141604059-0.50014-x · Cited by 11 · see citing works
Mwassi, H. A., Yahav, D., Ayada, G., Matsri, S., Margalit, I., Shargian, L., Bishara, J., & Atamna, A. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106590 · Cited by 8 · see citing works
Esophagitis in the Immunocompromised Host
Wilcox, C. M. (2012) · doi:10.1002/9781444346220.ch39 · Cited by 7 · see citing works
The Role of Resistance in Candida Infections: Epidemiology and Treatment
Sobel, J. D., & Akins, R. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-47266-9_18 · Cited by 6 · see citing works
Arzneimitteltherapie invasiver Candida- und Aspergillusinfektionen
Maschmeyer, G., & Ruhnke, M. (2002) · Der Internist · doi:10.1007/s00108-002-0713-7 · Cited by 6 · see citing works
Gastrointestinal Manifestations of AIDS
Wilcox, C. M. (2004) · Nutrition in Clinical Practice · doi:10.1177/0115426504019004356 · Cited by 6 · see citing works
Management of Oropharyngeal and Esophageal Candidiasis in Patients with Hiv Infection
Vazquez, J. A. (2010) · HIV Therapy · doi:10.2217/hiv.10.18 · Cited by 5 · see citing works
Levine, M. S. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-2332-6.50029-4 · Cited by 5 · see citing works
Anidulafungin: a novel echinocandin
Vázquez, J. A. (2005) · Therapy · doi:10.1586/14750708.3.1.39 · Cited by 5 · see citing works
Saleem, N., Ijaz, S., & Lodhi, O. (2015) · Journal of Medical Cases · doi:10.14740/jmc2337w · Cited by 5 · see citing works
Cartledge, J. D., & Freedman, A. (2011) · HIV Medicine · doi:10.1111/j.1468-1293.2011.00944_8.x · Cited by 4 · see citing works
Mucocutaneous and Deeply Invasive Candidiasis
Shoham, S., Nucci, M., & Walsh, T. J. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3935-5.00088-4 · Cited by 4 · see citing works
Esophageal Candidiasis in Two Dogs With Megaesophagus: A Case Report
Anderson, K. L., & Tefft, K. M. (2025) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.70184 · Cited by 2 · see citing works
Levine, M. S. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-5117-4.00020-9 · Cited by 2 · see citing works
The Role of Resistance in Candida Infections: Epidemiology and Treatment
Sobel, J. D., & Akins, R. A. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-595-8_18 · Cited by 2 · see citing works
Triazole therapy for mucocutaneous candidiasis in HIV-infected patients
Thomas, C. J. (1998) · Journal of the Association of Nurses in AIDS Care · doi:10.1016/s1055-3290(98)80031-9 · Cited by 2 · see citing works
Infective Esophagitis: a Review of Esophageal Diseases in HIV
Ali, A. A., Sanders, K., McCarthy, A. M., et al. (2023) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-023-00435-z · Cited by 2 · see citing works
“In a randomized control trial, itraconazole demonstrated comparable treatment response rates and side effect profile to fluconazole [8, 9].”
Andes, D. R., & Dismukes, W. E. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_5 · Cited by 3 · see citing works
Saleem, N., Ijaz, S., & Lodhi, O. (2015) · Journal of Medical Cases · doi:10.14740/jmc.v6i11.2337 · Cited by 1 · see citing works
GRAMAN, P. S. (2015) · Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases · doi:10.1016/b978-1-4557-4801-3.00099-0 · Cited by 1 · see citing works
Esophageal Infections and Disorders Associated with Acquired Immunodeficiency Syndrome
Wilcox, C. M. (2015) · Yamada's Textbook of Gastroenterology · doi:10.1002/9781118512074.ch51 · Cited by 1 · see citing works
Update gastroenterologie 1997 — Teil I
Fischbach, W., Groß, V., Schölmerich, J., Ell, C., Layer, P., Fleig, W. E., & Zirngibl, H. (1998) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/bf03043280 · Cited by 1 · see citing works
Esophagitis in the Immunocompromised Host
Callaway, J. P., & Wilcox, C. M. (2021) · doi:10.1002/9781119599692.ch43 · Cited by 1 · see citing works
Gastrointestinal Tract Infections
Haas, L., & Marsano, L. S. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-036-0_12
Infections in the Immunocompetent and Immunocompromised Patient
Brown, C., & Wilcox, C. M. (2010) · doi:10.1002/9781444327311.ch36
Drug-induced Injury, Infections, and Congenital and Miscellaneous Disorders
Mounajjed, T. (2019) · Springer eBooks · doi:10.1007/978-3-030-15573-5_5
Nichtrefluxbedingte Ösophaguskrankheiten
Mössner, J. (2005) · Springer eBooks · doi:10.1007/3-540-26660-7_2
GRAMAN, P. S. (2010) · Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases · doi:10.1016/b978-0-443-06839-3.00094-1
Nett, J. E., & Andes, D. R. (2010) · CRC Press eBooks · doi:10.1201/b13787-152
(2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5544-0.00022-2
Irwin, R. G., Groll, A. H., & Walsh, T. J. (1998) · Side effects of drugs annual · doi:10.1016/s0378-6080(98)80031-7
(2006) · Elsevier eBooks · doi:10.1016/b0-44-451005-2/00521-0
(2010) · Elsevier eBooks · doi:10.1016/b978-0-444-53272-5.50007-8
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00933-1
Stein, J. (2006) · Springer eBooks · doi:10.1007/3-540-37211-3_14
- Authors
- Barbaro, G., Barbarini, G., Calderon, W., Grisorio, B., Alcini, P., & Di Lorenzo, G.
- Affiliations
- Sapienza University of Rome (IT)
- ORCID
- Barbarini, G
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 1996-11
- Volume
- 111
- Issue
- 5
- Pages
- 1169-1177
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2034424215
- Cited by
- 78
- References
- 0
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 1 · 2019: 2 · 2018: 1 · 2017: 1 · 2015: 7 · 2014: 1 · 2012: 3
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › HIV/AIDS oral health manifestations
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- esophageal candidiasis, AIDS, fluconazole, itraconazole, antifungal therapy, treatment efficacy, treatment failure, HIV infection
- MeSH terms
- Adult, Antifungal Agents, Candidiasis, Esophagitis, Female, Follow-Up Studies, Humans, Male, Patient Compliance, Fluconazole, AIDS-Related Opportunistic Infections, Treatment Failure, Itraconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
